Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corcept starts pivotal Cushing’s syndrome study
In September, the company reported that the FDA had opened the investigational new drug application (IND) for Corlux for the treatment of endogenous Cushing’s syndrome, which allowed it
In September, the company reported that the FDA had opened the investigational new drug application (IND) for Corlux for the treatment of endogenous Cushing’s syndrome, which allowed it
The acquisition follows the US Federal Trade Commission’s early termination of the waiting period required by US antitrust law. With the completion of the acquisition, Reliant’s cardiovascular medicines
The acquisition gives GlaxoSmithKline marketing rights to Lovaza in the US and Puerto Rico. In addition to Lovaza, three other cardiovascular products marketed by Reliant – DynaCirc CR
In addition to the initial milestone payment, Elbion would be entitled to additional payments from Wyeth based on the achievement of further milestones. Payments to Elbion under the
Basen was launched in 1994 in Japan as an improving agent for postprandial hyperglycemia in diabetes mellitus, with its mechanism of action of delaying the digestion and absorption
Upon completion of the acquisition, which is subject to definitive agreements, Enzo will have local, directly owned presence from which to market its growing line of life sciences
The study is designed to evaluate the safety and efficacy of Actelion-1 in delaying disease progression and mortality in patients with pulmonary arterial hypertension (PAH). The SERAPHIN study
The iChem Velocity system is the first urinalysis system to employ Iris’s proprietary Kinetic Imaging technology that will optimize the sensitivity and dynamic range of the company’s urine
The European Commission approved Retacrit on the basis of strong, compelling safety and efficacy data, as well as compliance with extensive quality, clinical and non-clinical guidelines. Retacrit has
Under the terms of the agreement, Santaris Pharma will grant GlaxoSmithKline (GSK) options to drug candidates discovered and developed under the collaboration in up to four different viral